Skip to main content
CRVO
NASDAQ Life Sciences

Shareholders Approve 21.6% Equity Incentive Plan Expansion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$2.994
Mkt Cap
$26.943M
52W Low
$2.815
52W High
$13.13
52W Position info
6.4% above low
Off High info
77% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CRVO is trading near its 52-week low of $2.815 (6.4% above the low) on light trading volume (0.4× avg).

Summary

CervoMed shareholders approved an amendment to its equity incentive plan, authorizing the potential issuance of 2 million additional shares, which could lead to significant dilution.


Key Events · Financing and Capital Events · CRVO

  • Equity Incentive Plan Expanded

    Shareholders approved Amendment No. 1 to the CervoMed Inc. 2025 Equity Incentive Plan, which was previously disclosed in a DEF 14A filing on April 30, 2026.

  • Significant Potential Dilution

    The approved amendment allows for the potential issuance of an additional 2 million shares, representing approximately 21.6% of the company's currently outstanding common stock.

  • Routine Annual Meeting Matters Approved

    Shareholders also elected eight directors, ratified RSM US LLP as the independent auditor, and approved executive compensation on an advisory basis.


Analysis · CRVO · Life Sciences

Shareholders approved a significant expansion of the company's equity incentive plan, allowing for the potential issuance of an additional 2 million shares. This represents substantial potential dilution for existing shareholders, but it is a critical step for CervoMed to attract and retain talent, especially given its current financial distress and going concern warning. The ability to offer equity compensation is vital for a biotech company to continue its drug development programs and extend its operational runway.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRVO was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.9M. The 52-week trading range was $2.82 to $13.13. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRVO - Latest Insights

CRVO
Nov 16, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.48 info
Change: -$0.170 (-10%) info
Market Cap: $22.542M info
CRVO
Nov 06, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $1.48 info
Change: +$0.060 (+4%) info
Market Cap: $22.542M info
CRVO
Oct 29, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.48 info
Change: -$0.270 (-15%) info
Market Cap: $22.542M info
CRVO
Oct 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $1.48 info
Change: -$1.54 (-51%) info
Market Cap: $22.542M info
CRVO
Sep 28, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.48 info
Change: -$1.15 (-44%) info
Market Cap: $22.542M info